Related Experiment Videos
Long term therapy with 1,25(OH)2D3 in dialysis bone disease
Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association
|January 1, 1976
Summary
This study shows that 1,25-dihydroxyvitamin D3 effectively treats haemodialysis bone disease by improving calcium absorption and secondary hyperparathyroidism without causing hypercalcaemia. Patients also experienced enhanced muscle function.
Area of Science:
- Nephrology
- Endocrinology
- Bone Metabolism
Background:
- Haemodialysis bone disease, a complication of chronic kidney disease, involves impaired mineral metabolism and bone abnormalities.
- Secondary hyperparathyroidism is a common and serious complication in patients undergoing haemodialysis.
- Vitamin D deficiency and impaired calcium absorption contribute to bone disease in haemodialysis patients.
Purpose of the Study:
- To evaluate the efficacy and safety of 1,25-dihydroxyvitamin D3 in treating haemodialysis bone disease.
- To assess the impact of 1,25-dihydroxyvitamin D3 on calcium absorption, secondary hyperparathyroidism, and bone mineralization.
- To determine the effect on muscle strength in patients with haemodialysis bone disease.
Main Methods:
- Five patients with haemodialysis bone disease received daily doses of 1 to 1.5 mug of 1,25-dihydroxyvitamin D3 for 6-8 months.
- Evaluated changes in calcium absorption, serum calcium levels, parathyroid hormone (PTH), and alkaline phosphatase.
- Assessed histological and radiological improvements in secondary hyperparathyroidism and bone mineralization status.
- Monitored clinical and electromyographical measures of muscle power.
Main Results:
- Significant improvement in calcium absorption was observed without hypercalcaemia.
- Histological and radiological signs of secondary hyperparathyroidism improved, with decreased serum PTH and normalized alkaline phosphatase.
- Bone mineralization status showed improvement, although at a slower rate.
- Patients demonstrated significant clinical and electromyographical improvements in muscle power.
Conclusions:
- 1,25-dihydroxyvitamin D3 is a safe and effective treatment for haemodialysis bone disease.
- The treatment successfully addresses secondary hyperparathyroidism and improves calcium metabolism.
- Improvements in bone mineralization and muscle function suggest a broader therapeutic benefit in this patient population.